ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright [Yahoo! Finance]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside potential of 152.92%. Among the analysts bullish on the stock is Joseph Pantginis, an analyst at H.C. Wainwright, who assumed coverage on the company with a ‘Buy' rating and a $12 price target on December 16, according to TheFly. His price target implies about 367% upside from the current price. With ProKidney Corp. (NASDAQ:PROK) initiating a fresh approach to “postponing progressive kidney dysfunction,” the analyst believes the company's lead asset, rilparencel, exhibits the potential to redefine how chronic kidney disease is treated. Likoper/Shutterstock.com H.C. Wainwright highlighted that rilparencel, an investigational autologous cell therapy for patients living with chronic kidney disease and type 2 diabetes, has already demonstrated promising results across several Phase 1 and 2 trials. This inclu
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ProKidney to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- ProKidney (NASDAQ:PROK) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- ProKidney (NASDAQ:PROK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M [Seeking Alpha]Seeking Alpha
PROK
Earnings
- 11/10/25 - In-Line
PROK
Sec Filings
- 1/12/26 - Form 8-K
- 11/19/25 - Form EFFECT
- 11/14/25 - Form 4
- PROK's page on the SEC website